Achieving Increasingly Stringent Disease Control Criteria Was Associated with Greater Quality of Life Improvements in Patients with Active Psoriatic Arthritis: Results from BE OPTIMAL and BE COMPLETE/BE VITAL up to 1 Year
Author(s)
Kristensen LE1, Coates LC2, Mease PJ3, Merola JF4, Gisondi P5, Nash P6, Ogdie AR7, Tillett W8, Ink B9, Bajracharya R9, Taieb V10, Lambert J11, Willems D12, Walsh JA13
1The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, University of Oxford and Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, UK, 3Swedish Medical Center and Providence St. Joseph Health, University of Washington, Seattle, WA, USA, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, 5Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, 6School of Medicine, Griffith University, Brisbane, Australia, 7Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 8Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, UK, 9UCB Pharma, Slough, UK, 10UCB Pharma, Colombes, France, 11UCB Pharma, Irigny, 69, France, 12UCB Pharma, Brussels, Belgium, 13Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, USA
Presentation Documents
OBJECTIVES: To examine the association between achieving stringent disease control criteria and improvements in health-related quality of life (HRQoL) and work productivity in patients with psoriatic arthritis (PsA) to 1 year.
METHODS: Post hoc analysis of data from bimekizumab studies BE OPTIMAL (NCT03895203; biologic DMARD [bDMARD]-naïve) and BE COMPLETE/BE VITAL (NCT03896581/NCT04009499; TNF-α inhibitor inadequate response [TNFi‑IR]). Patients achieving disease control criteria using American College of Rheumatology (ACR), Psoriasis Area and Severity Index (PASI), minimal disease activity (MDA) or Disease Activity Index for PsA (DAPSA) at Week 52 (BE OPTIMAL) or Week 40 (BE COMPLETE/BE VITAL) were pooled regardless of treatment arm. Associations between criteria achievement and improvements from baseline in HRQoL (EQ‑5D‑3L VAS, EQ‑5D Utilities, SF‑36 PCS) and Work Productivity and Activity Impairment (WPAI) dimensions were assessed (observed case).
RESULTS: 90.4% and 86.8% patients completed Week 52 of BE OPTIMAL and BE COMPLETE/BE VITAL, respectively. Baseline mean (SD) EQ-5D-3L VAS (bDMARD‑naïve/TNFi-IR): 56.3 (20.0)/54.4 (20.4); overall work impairment score: 35.8 (26.6)/40.5 (27.9). At Week 52/40, patients achieving greater ACR responses demonstrated greater mean (95% CI) improvements in EQ-5D-3L VAS (bDMARD-naïve: <20%: 4.7 [1.1, 8.3], ≥20%–<50%: 7.2 [3.7, 10.7], ≥50%–<70%: 15.9 [11.4, 20.3], ≥70%: 26.6 [23.5, 29.7]; TNFi-IR: 2.3 [–2.5, 7.2], 11.5 [6.4, 16.6], 17.5 [11.8, 23.3], 32.9 [27.8, 37.9]) and greater reductions in percent overall work impairment (bDMARD‑naïve: <20%: –1.5 [–7.2, 4.3], ≥20%–<50%: –13.1 [–18.5, –7.8], ≥50%–<70%: –12.2 [–19.4, –5.0], ≥70%: –28.3 [–32.1, –24.6]; TNFi‑IR: –8.9 [–16.7, –1.1], –12.2 [–20.1, –4.3], –27.0 [–33.9, –20.2], –30.7 [–37.1, –24.3]). Trends were similar for ACR50+PASI100/MDA/DAPSA thresholds and improvements in EQ‑5D Utilities/SF-36 PCS/WPAI dimensions.
CONCLUSIONS: Achievement of increasingly stringent disease control criteria was associated with greater, clinically relevant improvements in HRQoL and work productivity up to 1 year in patients with PsA.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
PCR229
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), No Additional Disease & Conditions/Specialized Treatment Areas